DOCSLIB.ORG

The Brain Renin-Angiotensin System and Extrarenal Renin Detlev Ganten

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Brain Renin-Angiotensin System and Extrarenal Renin Detlev Ganten The Brain Renin-Angiotensin System and Extrarenal Renin Detlev Ganten Title of thesis: STUDIES ON THE EXISTENCE OF AN INDEPENDENT BRAIN RENIN-ANGIOTENSIN SYSTEM: A MODEL FOR EXTRARENAL TISSUE RENIN. Name: Detlev Ganten. Department: Experimental Medicine, McGill University. Degree: Ph.D. SUMHARY An enzyme, capable of catalyzing the reaction with renin substrate to form angiotensin is described in the brain of dogs, rats, sheep and man. This brain tissue iso-renin differs in important characteristics from renal renin. The enzyme persists at control-levels 12 days after nephrectomy. Renin substrate has been found equally in brain tissue of dogs. Angiotensin was extracted from brain of dogs which had been nephrectomized and in which plasma angiotensin was undetectable. This shows that angio­ tensin can be formed locally in the brain. An iso-renin of similar characteristics as brain iso-renin is described and partially characterized in aortic tissue and in adrenal glands. The independence of tissue iso-renin from kidney renin is supported by the fact that the two enzymes react diffe­ rently to the same physio-pathological stimuli. STUDIES ON THE EXISTENCE OF AN INDEPENDENT BRAIN RENIN­ ANGIOTENSIN SYSTEM: A MODEL FOR EXTRARENAL TISSUE RENIN. Det1ev Ganten, M.D. Submitted to the Facu1ty of Graduate Studies and Research of McGi11 University in partial fu1fi1ment of the requirement for the degree of Doctor of Phi1osophy. Department of Experimental Medicine, C1inica1 Research Institute, McGi11 University, Montreal, Canada. Montreal, Canada. August 1972. Det1ev Ganten 1973 FOR URSULA TABLE OF CONTENT ACKNOWLEDGMENTS l LIST OF FIGURES II LIST OF TABLES V LIST OF ABBREVIATIONS VII 1. INTRODUCTION ••.•••.•.•.••...••.•.••.••.•.•.•...•.•••... 1 2~ REVIEW OF THE LITERATURE 2.1. Components of the Renin-l1ngiotensin-System ..• 4 2.1. 1. Renin ........................................ 4 2.1. 2. Tissue Iso-Renin 6 2.1. 2.1. Uterus 7 2.1. 2.2. Salivary Glands 8 2.1. 2.3. Adrenal Glands 9 2.1. 2.4. Arterial lval! 10 2.1. 3. Pseudorenin ••••••••••••••.••••••••••••••••••• Il 2.1. 4. Renin Substrate (Angiotensinogen) 14 2.1. 5. Angiotensin 16 2.1. 6. Angiotensin l Converting Enzymes 18 2.1. 7. Antirenin .................................... 21 2.l. 8. Antiangiotensin .............................. 22 2.1. 9. Renin Inhibitors 23 2.1. 10. Angiotensinases 25 2.2. CZeQPanoe of Renin and Angiotensin from PZasma •...••..••.•..••.••••.•.•....•..•..•..• 26 2.3. Interaotion of the Components and CritioaZ EvaZuation of the CZassioaZ Renin-Angiotensin- System .........••....................•....... 29 2.4. ~ze BZood-Brain-Barrier 36 3. INVESTIGATIVE SECTION . ................................ 40 3.1. Methods for Renin and Angiotensin .••.•...••.. 40 3.1. 1. Plasma ....................................... 43 3.1. 2. Cerebrospina1 F1uid •.••••••.•••••••••.••..•.• 43 3.1. 3. Brain Tissue .•••••••••••••••••••••.•••.•••.•• 43 3.1. 4. Hesenteric Artery Branches .••••••••••••.•.••• 44 3.1. 5. Aortic Tissue •••••••••.••••••••••••••••••.••• 45 3.1. 6. Carotid Artery 45 3.1. 7. Adrena1 Glands 45 3.2. Measuren;ent.of Angiotensin in PZasma, CSF, and Bra"n T"ssue •...•.•.••••.•...•.••....••.. 1.6 3.3. Method for Measurement of Renin Substrate in PZasma and CSF .•..••••••....•.••••...••...•.. 48 3.4. Method for Measurement of Renin Substrate in Brain Tissue ................................. 48 3.5. Preparation of Different Renin Substrates •••. 51 3.5. 1. Dog Plasma "Standard" Substrate •••••••••••••• 51 3.5. 2. Purified Dog Plasma Substrate •••••••••••••••• 52 3.5. 3. lletero1ogous Substrates from Rabbit, Rat and Sheep ........................................ 53 3.5. 4. Synthetic Renin Substrate •••••••••••••••••••• 54 3.6. Pu~ification of Tissue Iso-Renins ..•........ 56 3.7. UZt~acent~ifugation of B~ain and Kidney Tissue ....................................... 57 3.8. '~isc" EZect~opho~esis on PoZyac~yZamide Ge Z. ••••••••••••••••••••••••••••••••••••••••• 60 3.9. Othe~ ftlethods ............................... 62 4. RESULTS (METHODOLOGICAL) •...••••.•...••.•...•.•.••.... 64 4.1. Specificity of the Renin Assay •............. 64 4.2. Identification of Angiotensin as the Froduct of the B~ain-Enzyme Subst~ate Reaction ...... 76 4.3. Compa~ison of B~ain Iso-Renin with Kidney' Renin ....................................... 80 4.4. ~e Pe~/eabiZity of the BZood-B~ain-B~~ie~ fol" Renin ................................... 91 4.5. UZt~acent~ifugation Studies .....•.......•... 94 5. RESULTS (PHYSIO-PATHOLOGICAL) .•••••••..•.••••.•.••.•.• 104 5.1. B~ain Iso-Renin in Cont~oZ and Neph~ectomized Dogs .••.•..•••••.•••••.•••.•..•.•••.••••••.. 104 5.2. nze P~esence of Renin Subst~ate and Angio- tensin in B~ain Tissue .........•............ Ill! 5.3. Iso-Renin, EZect~oZytes and CatechoZamines in B~ains of Dogs at Diffe~ent Ages ......... 120 5.4. Iso-Renin in A~te~iaZ Tissue ..........•..... 133 5.4. 1. Characterization .•.•..•••.•••..••..•.•..•... 133 5.4. 2. Independence of Iso-Renin in Arteria1 Tissue from Plasma and Kidney Renin ....••••••••...• 136 5.4. 2.1. Hemorrhage in Nephrectomized Dogs ••.••• 137 5'.4. 2.2. lIemorrhage in Nephrectomized Dogs with Reduced Sp1anchnic Vascu1ar Bed •••••••• 145 5.4. 2.3. Iso-Renin in Arteria1 Tissue from Normal and Nephrectomized Dogs ••••••••• 147 5.4. 2.4. Stimulation of Iso-Renin in Arteria1 Tissue by C1ipping of the Superior Mesenteric Artery ••••••••••.••••••••••• 151 5.5. Effeat of Aldosterone Administration on Plasma Renin AativitY3 Tissue Iso-Renins and Plasma EZeatrolytes •........................ 159 5.6. Effeat of Progesterone Administration on Plasma Renin AativitY3 Tissue Iso-Renins and Plasma EZeatrolytes .......•.•.•.......•...... 162 5.7. Effeat of Potassium Defiaienay on Plasma Renin Aativity3 Tissue Iso-Renins and Plasma EZectroZytes ................................. 166 5.8. Renin Aativity in other Extrarenal Tissues and Tissue Renin Aativity in Speaies other than Doga .................................................... 169 6. GENERAL DISCUSSION •••••••••••••••••••••••••••••••••••• 176 7. CLAIMS TO ORIGINALITY ••••••••••••••••••••••••••••••••• 194 8. SmmARY ........................................................................................... 197 9. RESl.Jr1.E ................................................................................................ 198 10.. BIBLIOGRAPHY.. .. .. .. .. .. .. .. .. .. .. • .. • .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .... 199 l ACKNOWLEDGMENTS l am deeply indebted to the following: Dr. Jacques Genest and Dr. Roger Boucher for providing the laboratory facilities and for their continued interest and support of my work. Dr. Daniel Trachewsky and Dr. John Grose for many improvements in the English presentation of the manuscript. l am also indebted to my colleagues for their friendly and invaluable collaboration: Dr. H.M. Brecht, Dr. G. Constantopoulos, Dr. P. Granger, Dr. K. Hayduk, Dr. K.P. Karsunky, Dr. M. Kusumoto, Dr. A. Marquez-Julio, and Dr. James Minnich. l wish to extend my gratitude to Miss C. Labarre, Mr. E. Pierre, Mr. D. Charbonneau, Mrs. D. Pazzi and Mrs. S. Olivieri for occasional and skillful technical assistance, Miss I. Morin for preparing the illustrations and Mrs. o. Desroches for typing this thesis. II LIST OF FIGURES FIGURE 1: Sahematia outZine of the renin-angiotensin system ............................................. 31 FIGURE 2: GeneraZ outZine of the proaedure for the measu- rement of pZasma and tissue renin aativity .••....•• 41 FIGURE 3: Effeat of inaubation time of brain iso-renin on angiotensin ,formation ....•....•.•..•...••.•.•.•.••. 67 FIGURE 4: Effeat.of in~reasing ~ounts of brain iso-renin 68 on ang~otens~n format~on ...••.•.•..•....•.•.••.••.. FIGURE 5: Effeat of different substrates on angiotensin formation •.•..•....•.•••.••.•......•••.•••.••.•..•. 75 FIGURE 6: ~ffeat of angiotensin antibodies on pressor materiaZ from 1:naubation of brain iso-renin •.•••..•....•...• 78 FIGURE 7: ~ffeat o.f pH on c;ngiotens~n formation with tissue ~so-ren~ns and k~dney ren~n .•••••..•••.•..•..••..•• 81 FIGURE 8: Comparison of angiotensin formation with purified renaZ renin and iso-renin from brain tissue of dogs •.•........•...............•................... 84 FIGURE 9: Effeat of tetradeaapeptide aonaentration on angio- tens'În fopmation ................................... 86 FIGURE 10: qisa-eZeatrophoresis of purified renin extraats 89 FIGURE Il: UZtraaentrifugation studies: renin aativity in primary ae ZZ fraations ....•..••...•.•.••••..•.•...• 97 FIGURE 12: UZtraaentrifugation studies: renin aativity in subfraations of prima~ mitoahondriaZ fraations 98 FIGURE 13: Effeat of bi ZateraZ nephreatomy on brain iso-renin in doge ............................................ 108 FIGURE 14: Po Zyethy Zene tubing sys tem for repeated peri tonea'l diaZysis ........................................... 109 FIGURE 15: Effeat of bi ZateraZ nephreatomy on iso-renin aon·, tent of aaudate nua Zeus in brain tissue of doga .•.. 113 FIGURE 16: ~(feat of angiotensin antibodies on angiotensin extraat from brain tissue ....•.••..•••.....•.•.••.. 117 III FIGURE 17: f.0~hologiaal aspeat of dog brains at different ages ............................................ 121 FIGURE 18: Comparison of brain iso-renin and plasma renin in dogs of different ages •....•..••.••..••..••.•. 123 FIGURE 19: Water and eleatrolyte aontent of brain tissue (frontal aortex) from dogs of different ages ••••. 126 FIGURE 20: Potassium aontent and iso-renin of brain tissue (aœ<date nualeus)
Load more

Recommended publications
  • October 24–26, 2021 2
    SCIENCE · INNOVATION · POLICIES WORLD HEALTH SUMMIT BERLIN, GERMANY & DIGITAL OCTOBER 24–26, 2021 2 “No-one is safe from COVID-19; “All countries have signed up to Universal no-one is safe until we are all Health Coverage by 2030. But we cannot safe from it. Even those who wait ten years. We need health systems conquer the virus within their that work, before we face an outbreak own borders remain prisoners of something more contagious than within these borders until it is COVID-19; more deadly; or both.” conquered everywhere.” ANTÓNIO GUTERRES Secretary-General, United Nations FRANK-WALTER STEINMEIER Federal President, Germany “We firmly believe that the “All pulling together—this must rights of women and girls be the hallmark of the European are not negotiable.” Health Union. I believe this can NATALIA KANEM be a test case for true global Executive Director, United Nations Population Fund (UNFPA) health compact. The need for leadership is clear and I believe the European Union must as- sume this responsibility.” “The lesson is clear: a strong health URSULA VON DER LEYEN system is a resilient health system. Health President, European Commission systems and preparedness are not only “Governments of countries an investment in the future, they are the that are doing well during foundation of our response today.” the pandemic have not TEDROS ADHANOM GHEBREYESUS Director-General, World Health Organization (WHO) only shown political leader- ship, but also have listened “If we don’t address the concerns and to scientists and followed fears we will not do ourselves a favor. their recommendations.” In the end, it is about how technology SOUMYA SWAMINATHAN Chief Scientist, World Health can be advanced as well as how Organization (WHO) we can make healthcare more human.” BERND MONTAG President and CEO, Siemens Healthineers AG, Germany “The pandemic has brought to light the “Academic collabo ration is importance of digital technologies and in place and is really a how it can radically bridging partnership.
    [Show full text]
  • Research Uses of Peptides from the Manning Lab 1980 – 2019
    Research Uses of Peptides from the Manning Lab 1980 – 2019 Over 3,000 samples have been donated to over 820 investigators (some multiple times) in the U.S. and worldwide for their own independent studies. See listings below. These studies have resulted in over 2,000 publications by these investigators. 1. Professor Roger Acher Laboratoire De Chimie Biologique Faculté des Sciences de l’Université de Paris 96, Boulevard Raspail-Paris V1 FRANCE 2. Eli Y. Adashi, M.D. Obstetrics & Gynecology University of Maryland School of Medicine & Hospital 22 South Greene Street Balitmore, MD 21201 3. Greti Aguilera, M.D. Chief Section on Endocrine Physiology DEB, NICHD, NIH Building 10, Room 10N262 10 Center Drive, MSC 1862 Bethesda, MD 20892-1862 4. Dr. K. Al Barazanji Mechanistic Pharmacology Dept. Vascular Biology SmithKline Beecham Pharmaceuticals The Frythe Welwyn, Hertfordshire, AL6 9AR UNITED KINGDOM 5. H. Elliott Albers, Ph.D. Professor of Biology and Psychology Georgia State University Department of Biology College of Arts and Sciences P.O. Box 4010 Atlanta, GA 30302-4010 6. Saad Al-Damluji, B.Sc., MRCP Lecturer in Endocrinology The Medical College of St. Bartholomew’s Hospital West Smithfield, LONDON, EC1A 7BE ENGLAND 7. Natalie Alexander, Ph.D. Department of Medicine University of Southern California School of Medicine 2025 Zonal Avenue Los Angeles, CA 90033 8. O.F.X. Almeida, Ph.D. Max-Planck-Institut Für Psychiatrie Deutsche Forschungsanstalt Für Psychiatrie Abteilung Neuropharmakologie AM Klopferspitz 18A 8033 Planegg-Martinsried WEST GERMANY 9. Dr. Meenakshi Alreja Associate Professor of Psychiatry and Neurobiology Yale University School of Medicine CMHC 335A, 34 Park Street New Haven, CT 06508 10.
    [Show full text]
  • World Health Summit Berlin, Germany October 09–11, 2016
    SCIENCE · INNOVATION · POLICIES WORLD HEALTH SUMMIT BERLIN, GERMANY OC TOBER 09–11, 2016 FEDERAL FOREIGN OFFICE | BERLIN I am convinced the “ World Health Summit will add valuable The World Health Summit impetus and wish all “ is an excellent venue for participants interesting expert discussion on the and enlightening days. health topics that move us Hermann Gröhe Federal Minister of Health, Germany” worldwide. We can expect it to deliver valuable input. Angela Merkel Chancellor of the ” Your involvement and Federal Republic of Germany “ your declarations at this World Health Summit will play an important role in informing the international community. François Hollande President of the French Republic ” FACTS WORLD HEALTH SUMMIT 2016 | 3 3 DAYS · 40 SESSIONS · 250 SPEAKERS From October 9–11, the 8th World Health Summit will once Patronage again draw international experts from academia, politics, Angela Merkel Federal Chancellor of Germany the private sector, and civil society to the German Federal François Hollande Foreign Oce in Berlin. President of France Jean-Claude Juncker At the World Health Summit (WHS), more than 1,500 stakeholders and President of the decision-makers from every field in the healthcare spectrum will work European Commission together to find solutions to global health challenges. Presidents 2016 The world’s foremost strategic forum for global health, it promotes thought Antoine Flahault leadership in science and global health agendas. The World Health Summit University of Geneva was founded in 2009 on the occasion
    [Show full text]
  • Global Health – Do Think Tanks Matter?
    Global Health – Do Think Tanks Matter? Organised by the Global Health Programme at the Graduate Institute Biographies of Speakers 13 November 2015 Maison de la paix The Graduate Institute, Geneva WELCOME AND INTRODUCTORY REMARKS BY THE MODERATOR OF THE SESSION ILONA KICKBUSCH Director, Global Health Programme, the Graduate Institute Ilona Kickbusch is the Director of the Global Health Programme at the Graduate Institute of International and Development Studies, Geneva. She is senior advisor to the Regional Directors of the WHO Regional Offices for Europe and the Eastern Mediterranean. She has been deeply involved in the development of the Health 2020 European health policy framework. She is a member of the independent Ebola interim assessment panel of the WHO. In Switzerland, she serves on the executive board of the Careum Foundation and on the expert panel to the Federal Councillor to advise on the implementation of the Swiss Health Strategy 2020. She has contributed to innovation in health in many ways throughout her career and now advises organisations, government agencies and the private sector on policies and strategies to promote health at the national, European and international level. She has worked with the WHO at various levels and in academia as professor at Yale University. She has received honorary doctorates from the Nordic School of Public Health and the University of Girona. She has published widely and is a member of a number of advisory boards in both the academic and health policy arenas. She has received many awards. Her key areas of work relate to Global Health Governance, Health Security, Public Health, Health Promotion, Health Literacy, and Health in All Policies.
    [Show full text]
  • Detlev Ganten
    Detlev Ganten * 28. 3. 1941 Lüneburg Der Mediziner Detlev Ganten arbeitet in der Bluthochdruckforschung und über die molekulare Genetik von Herz-Kreislauf-Erkrankungen. 1997/98 war Ganten Präsident der GDNÄ und referierte z. B. 1994 in Hamburg über Die Genetik des Bluthochdrucks: Molekulare Analyse einer Volkskrankheit. Detlev Ganten studierte ab 1962 Medizin in Würzburg, Montpellier (Frankreich) und Tübingen und war an der chirurgischen Abteilung des französischen Krankenhauses in Marrakesch tätig. Das Studium schloss er 1968 mit der Promotion ab. Zwischen 1969 und 1973 hielt er sich für For- schungszwecke am Clinical Research Institute in Montreal auf und erwarb den Doctor of Philosophy (PhD) von der McGill University. 1975 erhielt Ganten einen Ruf an das Pharmakologische Institut der Universität Heidel- berg und war anschließend ab 1992 Gründungsdirektor des Max-Delbrück- Centrums für Molekulare Medizin in Berlin-Buch. Parallel dazu war Ganten bis 2004 Professor für Klinische Pharmakologie am Universitätsklinikum der FU Berlin. In seiner wissenschaftlichen Arbeit beschäftigt sich Ganten insbesondere mit dem hormonalen Renin-Angiotensin-System, das u.a. für die Erhöhung des Blutdrucks verantwortlich ist. Daneben forscht er zur An- wendung transgener Techniken im Bereich der Herz-Kreislauf-Regulation und zu den genetischen Ursachen von Bluthochdruck. Ganten ist Heraus- geber des Journal of Molecular Medicine und des Handbook of Experimental Phar- macology. Außerhalb der wissenschaftlichen und medizinischen Arbeit war Gan- ten von 1993 bis 1998 Mitglied im Wissenschaftsrat der Bundesrepublik Deutschland, saß von 2002 bis 2007 im Nationalen Ethikrat und war von 2004 bis 2008 Vorstandsvorsitzender der Charité. Zwischen 1997 und 2001 war er Präsident der Helmholtz-Gemeinschaft Deutscher Forschungszent- ren.
    [Show full text]
  • M8 Alliance Expert Meeting on Migrants' and Refugees' Health 23
    M8 Alliance Expert Meeting on Migrants’ and Refugees’ Health 23-24 June 2017 Venue: Rectorate Building, Sapienza University of Rome, P.le Aldo Moro 5, Rome Hosted by Sapienza University of Rome in cooperation with Charité – Universitätsmedizin Berlin, the University of Geneva, the University of Montreal, the Université Sorbonne Paris Cité, the Centre Virchow-Villermé for Public Health Paris-Berlin, Tehran University of Medical Sciences and the Italian Society of Migration Medicine Overall Chair: Luciano Saso, Faculty of Pharmacy and Medicine, Vice-Rector for European University Networks Sapienza University, Sapienza's Representative in the M8 Alliance 23 June, 2017 11.00 Conferral of Honorary Doctorate on Prof. Detlev Ganten (Senate Hall, Rectorate Building, 1st floor) 13:00-14:00 Registration and light lunch (Room “Organi Collegiali”, Rectorate Building, ground floor) 14:00 -14:25 Welcome Addresses Eugenio Gaudio, Rector of Sapienza University of Rome Detlev Ganten, President of the World Health Summit, Berlin Delegate of Beatrice Lorenzin, Minister of Health, Italy Susanne Wasum-Rainer, Ambassador, Embassy of the Federal Republic of Germany in Italy Hinrich Thölken, Ambassador, Permanent Representation of the Federal Republic of Germany to the International Organizations in Italy 14:25 -14:45 Introduction Paolo Villari, Director of the Department of Public Health and Infectious Diseases, Sapienza University of Rome Axel Pries, Dean, Charité, Universitätsmedizin Berlin Vincenzo Vullo, Dean of the Faculty of Pharmacy and Medicine, Sapienza University of Rome Sebastiano Filetti, Dean of the Faculty of and Medicine and Dentistry, Sapienza University of Rome Massimo Volpe, Dean of the Faculty of and Medicine and Psychology, Sapienza University of Rome 14:45-17:00 Session 1A.
    [Show full text]
  • 2 of the Collège De France
    The Letter 2 of the Collège de France N°2 Academic year 2006-2007 Editorial The Collège de France’s new Scientific and Strategic Orientation Committee (COSS) by Pierre Corvol Administrator ‘Today’s world is seeking references, reasons to marvel, of the Collège de France ambitious motivating projects. With the sole objective of Professor, furthering knowledge, basic research – that essentially holder of the Chair of Experimental Medicine disinterested research which demands real collaboration at international level – is one of the paths on that quest. Science is and will always remain a factor of emancipation for humans the university world through the PhD schools, increasing and it is important today to emphasize that obvious fact. In this relations with foreign universities, and developing research at the context, the Collège de France has a unique position in France Collège itself. Today a progress report is indispensable. The and in Europe but also in the world.’ These are the introductory Collège will be attentive to the COSS’s opinions on these points, lines of the Annual Report of the International Scientific and as these will enable it to focus its strategy on the objectives that Strategic Orientation Committee (COSS) submitted to the the Committee has reviewed and revised. President of the Republic, the Prime Minister and the Collège de France’s supervisory ministries in May 2004. The COSS meeting in March 2007 enabled it to make contact with the members of the extended executive of the The creation of the COSS in 2003, on the Collège’s Collège and certain professors at the Cardinal Lemoine and initiative, stemmed from the wish to benefit from eminent Ulm sites.
    [Show full text]
  • World Health Summit Berlin, Germany October 15–17, 2017
    S ECCI N E · InnOVATION · POLICIES WORLD HEALTH SUMMIT B ERLIN, GERMANY O CTOBER 15–17, 2017 FACTS WORLD HEALTH SUMMIT 2017 | 3 3 DAYS · 40 SESSIONS · 250 SPEAKERS From October 15–17, the 9th World Health Summit will draw Patronage inter national experts from academia, politics, the private sector, Angela Merkel and civil society to Berlin. Chancellor of the Federal Republic of Germany At the World Health Summit (WHS), more than 1,600 stakeholders François Hollande * and decision-makers from over 80 countries and every field in the President of France healthcare spectrum will work together to find solutions to global Jean-Claude Juncker * health challenges. President of the European Commission The world’s foremost strategic forum for global health, it promotes thought leadership in science and advances global health agendas. Presidents 2017 The World Health Summit was founded in 2009 on the occasion of Hélène Boisjoly the 300th anniversary of Berlin’s Charité Hospital. Université de Montréal Detlev Ganten Charité – Universitätsmedizin Berlin PROGRAM STRUCTURE Participants SUNDAY, OCT 15, 2017 • More than 1,600 decision makers 10:30 from over 80 countries on site 13:00 • More than 3,000 people 15:00 worldwide via online live-stream 17:00 WHS OPENING CEREMONY Results • The M8 Alliance Declaration MONDAY, OCT 16, 2017 • Session Reports 9:00 • Statements and recommendations 11:00 made at the WHS are passed on to 13:00 WHS Startup Track National Academies, Governments, 14:00 and International Organizations 16:00 19:00 WHS Night Regional Meetings
    [Show full text]
  • Curriculum Vitae Professor Dr. Detlev Ganten
    Curriculum Vitae Professor Dr. Detlev Ganten Name: Detlev Ganten Born: 28 March 1941 Major scientific interests: Pathophysiology and molecular biology of high blood pressure, Public Health, Bioethics Academic and Professional Career 2010 Guest Professorship, Collège de France, Paris, France since 2009 President World Health Summit; Chairman of Board of Trustees of the Max Planck Institute of Colloids and Interfaces and Max Planck Institute of Molecular Plant Physiology, Germany since 2005 Chairman of the Board, Charité Foundation, Germany 2004 ‐ 2008 Chief Executive Officer, Charité Berlin, Germany 1991 ‐ 2004 Founding Director, Max Delbrück Center for Molecular Medicine (MDC) Berlin‐ Buch, Germany 1975 Professor of Pharmacology, University of Heidelberg, Germany 1973 Ph.D., McGill University, Montreal, Canada 1969 ‐ 1973 Research Fellow, Clinical Research Institute, Université de Montreal, Canada 1968 M.D. degree, University of Tübingen, Germany Project coordination, Membership in collaborative research projects (Selection) since 2011 Board of Trustees, University Paris Sciences Lettres PSL since 2011 Scientific Advisory Board, University Sorbonne Paris Cité since 2009 President of the World Health Summit Nationale Akademie der Wissenschaften Leopoldina www.leopoldina.org 1 since 2009 Chairman of Board of Trustees of the Max Planck Institute of Colloids and Interfaces and Max Planck Institute of Molecular Plant Physiology, Potsdam, Germany since 2009 Scientific Advisory Board, Agence Nationale der Recherche (ANR), Paris, France since
    [Show full text]
  • Value-Based Health Care in the Digital Era
    VALUE-BASED HEALTH CARE IN THE DIGITAL ERA December 18, 2018 Imagine Institute 24, Boulevard de Montparnasse 75015 Paris Sous le haut patronage de Madame Agnès Buzyn, ministre des Solidarités et de la Santé 2ND EDITION - INTERNATIONAL CONFERENCE MEMBERS OF THE SCIENTIFIC COMMITTEE CHAIRMAN OF THE SCIENTIFIC COMMITTEE We stand at an inflection point. Health systems and stakeholders are increasingly being Ran Balicer (ISR) David Bates (USA) Adam Donglei Feng (CHN) held accountable for the value their actions and products provide to patients and society at Founder and Director Professor of Health Professor, Wan Da Fullway large. Healthcare ought to be driven by a relentless focus on delivering outcomes that truly Clalit Research Policy & Management, Healthcare, General Manager & Institute Harvard T.H . Chan Co- founder Shanghai SimMed matter to patients. However, the emergence of value-based health care is hindered by a lack School of Public Health Technology Co of transparent and standardized outcome data. Digital solutions can play an instrumental role in transforming health systems in an unprecedented way. But how do we get there? We invite you to join leaders & pioneers from around the world to share experience on pilots & initiatives around the implementation of value-based health care, the adoption of digital standards, to expectations in payment reforms and access to quality healthcare. Detlev Ganten (GER) Véronique L. Roger (FRA) Lise Rochaix (FRA) Gregory Katz President & Founder Founding Director Center for Chaired Professor of Chaired Professor of Innovation Management & Value in Health University World Health Summit the Science of Health Care Health Economics, Chair Paris-Descartes Medical School, Director of Research, Elsan, Chairman of the Delivery, Mayo Clinic Hospinomics, Sorbonne University & Paris School Think Tank Digital Leaders in Health.
    [Show full text]
  • List of Speakers (In Alphabetical Order)
    List of speakers (in alphabetical order) Dr. Laurent Abel Head, Laboratory of Human Genetics of Infectious Diseases INSERM - Paris Descartes University - Imagine Institute for Genetic Diseases, FRANCE Pr. Moulay Hicham Afif Professor of pulmonology at the Faculty of Medicine and Pharmacy of Casablanca - Director of Ibn Rochd University Hospital Center in Casablanca - Head of pulmonology department at Ibn Rochd University Hospital Center - President of Moroccan society of Respiratory Diseases - President of Moroccan univerity college of pulmonology - Member of scientific advisory committee of national program for prevention and control of influenza and acute respiratory infections, Ministry of Health - Faculty of Medicine and Pharmacy, Hassan II University & Ibn Rochd University Hospital Center, Casablanca - Ibn Rochd University Hospital Center, Casablanca, Faculty of Medicine and Pharmacy, Hassan II University & Ibn Rochd University Hospital Center, Casablanca, MOROCCO Dr. Avelin F. Aghokeng Virologist – Joint Research Unit MIVEGEC - Department of Virology - Research Institute for Development and University of Montpellier, France - Director of CDC Virology Laboratory - Centers for Disease Control and Prevention (CDC) - U.S. President's Emergency Plan for AIDS Relief - Global AIDS Program (GAP), Abidjan, Côte d’Ivoire - Institute for research and development (IRD), Montpellier, France - Coordinator of the “HIV DRUG RESISTANCE IN SOUTH” Group at ANRS – France - Expert Member of the WHO HIVResNet Laboratory Working Group for surveillance of HIV Drug Resistance, Member of the ANRS Scientific Expert Panel - Virology Laboratory, Yaoundé, CAMEROUN- International center of medical research of Franceville, GABON Pr Jean François Allilaire Permanent executive officer of French Academy of medicine, FRANCE Pr. Christian Boitard Member of the National Academy of Medicine - Professor of Clinical Immunology - Université de Paris - Director, Institute Physiopathology, Metabolism, Nutrition (AVIESAN), FRANCE Dr.
    [Show full text]
  • UNESCO Paris
    VALUE-BASED HEALTH CARE IN THE DIGITAL ERA December 18, 2018 UNESCO Paris Sous le haut patronage de Madame Agnès Buzyn, ministre des Solidarités et de la Santé 2ND EDITION - INTERNATIONAL CONFERENCE SCIENTIFIC COMMITTEE’S MEMBERS SCIENTIFIC COMMITTEE’S CHAIRMAN We stand at an inflection point. Health systems and stakeholders are increasingly being Ran Balicer (ISR) David Bates (USA) Adam Donglei Feng (CHN) held accountable for the value their actions and products provide to patients and society at Founder and Director Professor of Health General Manager & Co- large. Healthcare ought to be driven by a relentless focus on delivering outcomes that truly Clalit Research Policy & Management, founder Shanghai SimMed Institute Harvard T.H . Chan Technology Co matter to patients. However, the emergence of value-based health care is hindered by a lack School of Public Health of transparent and standardized outcome data. Digital solutions can play an instrumental role in transforming health systems in an unprecedented way. But how do we get there? We invite you to join leaders & pioneers from around the world to share experience on pilots & initiatives around the implementation of value-based health care, the adoption of digital standards, to expectations in payment reforms and access to quality healthcare. Detlev Ganten (GER) Véronique L. Roger (FRA) Lise Rochaix (FRA) Gregory Katz President & Founder Founding Director Center for Chair Hospinomics, Chair of Innovation Management & Value in Health University Paris- World Health Summit the Science of Health Care University Paris-Sorbonne Descartes Medical School, Director of Research, Elsan, Chairman of the Think Delivery Mayo Clinic & Paris School of Economics tank Digital leaders in Health.
    [Show full text]